Protocol Ledger

NCT04256317 · Phase II/III · RECRUITING

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Interventional Phase II/III clinical trial protocol NCT04256317 sponsored by Taiho Oncology in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-05-21 Enrollment: 316 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04256317
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)316 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04256317
Protocol FieldVerified Registry Value
NCT IdentifierNCT04256317
Consolidated Lead SponsorTaiho Oncology
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment316 participants (ESTIMATED)
Registered Start Date2020-05-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI